Siemens Fonds Invest GmbH Purchases Shares of 27,722 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Siemens Fonds Invest GmbH acquired a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 27,722 shares of the company's stock, valued at approximately $611,000.

Other hedge funds have also added to or reduced their stakes in the company. Oarsman Capital Inc. purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter worth about $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at $44,000. Ameliora Wealth Management Ltd. bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at $66,000. IFP Advisors Inc increased its holdings in shares of Teva Pharmaceutical Industries by 96.1% during the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after acquiring an additional 1,960 shares in the last quarter. Finally, Quadrant Capital Group LLC increased its holdings in shares of Teva Pharmaceutical Industries by 27.7% during the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after acquiring an additional 949 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock traded down $0.76 during trading hours on Friday, reaching $16.77. The company had a trading volume of 19,852,269 shares, compared to its average volume of 10,105,614. The business has a fifty day moving average price of $15.52 and a 200-day moving average price of $17.37. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80. The firm has a market cap of $19.01 billion, a PE ratio of -11.57, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. The company had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Teva Pharmaceutical Industries's revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.48 earnings per share. Sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on TEVA shares. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday. They set a "buy" rating and a $25.00 price target for the company. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their price target for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Finally, Bank of America lifted their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $24.50.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.